Spero Therapeutics
Spero Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, developing therapies for immunology and inflammatory diseases. Its lead immunology program SP001 is an investigational anti-CD40L antibody. Spero also developed tebipenem pivoxil, marketed as Utebzi, in collaboration with GSK.
Key facts
| CAGE Code | 7SK81 |
|---|---|
| Legal Name | Spero Therapeutics, Inc. |
| Company Operating Status | Active |
| Full Address | 675 Massachusetts Avenue, 14th Floor, Cambridge, MA 02139, United States |
| Previous Name | Spero Therapeutics, LLC |
| Stock Symbol | SPRO |
| Ticker Symbol | SPRO |
| Wellfound ID | spero-therapeutics |
| Wikidata ID | Q30288957 |
Contact details
Email and phone for Spero Therapeutics are available to signed-in members of CliffBio.
Sign in to view